JAMMI最新文献

英文中文

AMMI Canada 2023 update on influenza: Management and emerging issues 加拿大AMMI 2023年流感最新情况:管理和新出现的问题

Q3 Medicine

JAMMI

Pub Date : 2023-10-23 DOI: 10.3138/jammi-2023-07-12

Robyn Harrison, Samira Mubareka, Jesse Papenburg, Tilman Schober, Upton D Allen, Todd F Hatchette, Gerald A Evans

引用次数: 0

Antibiotic treatment durations for pyogenic liver abscesses: A systematic review 化脓性肝脓肿的抗生素治疗时间:系统回顾

Q3 Medicine

JAMMI

Pub Date : 2023-10-12 DOI: 10.3138/jammi-2023-0004

Jennifer Curran, Catherine Mulhall, Ruxandra Pinto, Mohamed Bucheeri, Nick Daneman

Background: We sought to systematically review the existing research on pyogenic liver abscesses to determine what data exist on antibiotic treatment durations. Methods: We conducted a systematic review and meta-analysis of contemporary medical literature from 2000 to 2020, searching for studies of pyogenic liver abscesses. The primary outcome of interest was mean antibiotic treatment duration, which we pooled by random-effects meta-analysis. Meta-regression was performed to examine characteristics influencing antibiotic durations. Results: Sixteen studies (of 3,933 patients) provided sufficient data on antibiotic durations for pooling in meta-analysis. Mean antibiotic durations were highly variable across studies, from 8.4±5.3 to 68.9±30.3 days. The pooled mean treatment duration was 32.7 days (95% CI 24.9 to 40.6 days), but heterogeneity was very high ( I 2 = 100%). In meta-regression, there was a non-significant trend towards decreased mean antibiotic treatment durations over later study years (−1.14 days/study year, 95% CI −2.74, +0.45, p = 0.16). Mean treatment duration was not associated with mean age of participants, percentage of infections caused by Klebsiella spp., percentage of patients with abscesses over 5 cm in diameter, percentage of patients with multiple abscesses, and percentage of patients receiving medical management. No randomized trials have compared treatment durations for pyogenic liver abscess, and no observational studies have reported outcomes according to treatment duration. Conclusions: Among studies reporting on antibiotic durations for pyogenic liver abscess, treatment practices are highly variable. This variability does not seem to be explained by differences in patient, pathogen, abscess, or management characteristics. Future RCTs are needed to guide optimal treatment duration for patients with this complex infection.

背景:我们试图系统地回顾现有的关于化脓性肝脓肿的研究，以确定抗生素治疗持续时间的数据。方法:我们对2000年至2020年的当代医学文献进行了系统回顾和荟萃分析，寻找有关化脓性肝脓肿的研究。主要终点是平均抗生素治疗时间，我们通过随机效应荟萃分析汇总了这些数据。meta回归分析了影响抗生素持续时间的特征。结果:16项研究(3,933例患者)提供了足够的抗生素持续时间数据，用于荟萃分析。各研究的平均抗生素持续时间差异很大，从8.4±5.3天到68.9±30.3天不等。合并平均治疗时间为32.7天(95% CI 24.9 ~ 40.6天)，但异质性非常高(i2 = 100%)。在meta回归中，在随后的研究年中，平均抗生素治疗持续时间减少的趋势不显著(- 1.14天/研究年，95% CI - 2.74， +0.45, p = 0.16)。平均治疗时间与参与者的平均年龄、克雷伯氏菌感染的百分比、直径大于5厘米的脓肿患者的百分比、多发脓肿患者的百分比以及接受医疗管理的患者的百分比无关。没有随机试验比较化脓性肝脓肿的治疗时间，也没有观察性研究报告治疗时间的结果。结论:在报告化脓性肝脓肿的抗生素持续时间的研究中，治疗方法变化很大。这种差异似乎不能用患者、病原体、脓肿或治疗特点的差异来解释。需要未来的随机对照试验来指导这种复杂感染患者的最佳治疗时间。

{"title":"Antibiotic treatment durations for pyogenic liver abscesses: A systematic review","authors":"Jennifer Curran, Catherine Mulhall, Ruxandra Pinto, Mohamed Bucheeri, Nick Daneman","doi":"10.3138/jammi-2023-0004","DOIUrl":"https://doi.org/10.3138/jammi-2023-0004","url":null,"abstract":"Background: We sought to systematically review the existing research on pyogenic liver abscesses to determine what data exist on antibiotic treatment durations. Methods: We conducted a systematic review and meta-analysis of contemporary medical literature from 2000 to 2020, searching for studies of pyogenic liver abscesses. The primary outcome of interest was mean antibiotic treatment duration, which we pooled by random-effects meta-analysis. Meta-regression was performed to examine characteristics influencing antibiotic durations. Results: Sixteen studies (of 3,933 patients) provided sufficient data on antibiotic durations for pooling in meta-analysis. Mean antibiotic durations were highly variable across studies, from 8.4±5.3 to 68.9±30.3 days. The pooled mean treatment duration was 32.7 days (95% CI 24.9 to 40.6 days), but heterogeneity was very high ( I 2 = 100%). In meta-regression, there was a non-significant trend towards decreased mean antibiotic treatment durations over later study years (−1.14 days/study year, 95% CI −2.74, +0.45, p = 0.16). Mean treatment duration was not associated with mean age of participants, percentage of infections caused by Klebsiella spp., percentage of patients with abscesses over 5 cm in diameter, percentage of patients with multiple abscesses, and percentage of patients receiving medical management. No randomized trials have compared treatment durations for pyogenic liver abscess, and no observational studies have reported outcomes according to treatment duration. Conclusions: Among studies reporting on antibiotic durations for pyogenic liver abscess, treatment practices are highly variable. This variability does not seem to be explained by differences in patient, pathogen, abscess, or management characteristics. Future RCTs are needed to guide optimal treatment duration for patients with this complex infection.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135967672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective review of rates of sexually transmitted and blood-borne infection (STBBI) testing in provincial corrections facilities in Newfoundland and Labrador 纽芬兰和拉布拉多省惩戒机构性传播和血源性感染(STBBI)检测率的回顾性审查

Q3 Medicine

JAMMI

Pub Date : 2023-09-18 DOI: 10.3138/jammi-2022-0036

Cindy Whitten, Alison Turner, Brittany Howell, Brooklyn Sparkes, Rosemary Ricciardelli, Peter Daley

Background: Sexually transmitted and blood borne infection (STBBI) testing is recommended for people who are incarcerated (PWAI). We sought to determine the rate of STBBI testing during admissions to provincial correctional institutions in Newfoundland and Labrador (NL). Methods: This retrospective cohort study collected the identification of all admissions records in provincial correctional facilities in NL between July 1, 2020 and June 31, 2021 using the Provincial Corrections Offender Maintenance System database. Admissions to provincial detention centers were excluded. Records were linked with STBBI results, when available, within the electronic medical record (Meditech) using demographics. Testing rates, STBBI positivity rates, and univariate analysis of predictors for STBBI testing were completed. Results: Of the 1,824 admissions identified, 1,716 were available for linkage to laboratory results. Admissions to detention centers ( n = 105) were excluded. Any STBBI test result was available for 72 (4.5%) of admissions. No admission had complete testing for all STBBI. Facility testing rates ranged from 1.9 to 11.2% and 37.5% of STBBI tests had any positive results. Sixteen out of the 21 (76.2%) hepatitis C virus (HCV) antibody positives received HCV RNA testing, and 11/16 (88.8%) were HCV RNA positive. Institution ( p = 0.001) and sex ( p = 0.004) were found to be significant predictors of STBBI testing, while age was not significant ( p = 0.496). Conclusions: STBBI testing rates were low in provincial correctional facilities in NL, and STBBI prevalence, especially for HCV, was high among those tested. Strategies to increase the rate of testing could contribute to STBBI control in corrections facilities.

背景:性传播和血源性感染(STBBI)检测被推荐给被监禁的人(PWAI)。我们试图确定在纽芬兰和拉布拉多省(NL)的省级惩教机构的招生STBBI测试率。方法:本回顾性队列研究收集了2020年7月1日至2021年6月31日期间NL省级惩教机构的所有入院记录，使用省级惩教罪犯维护系统数据库。进入省级看守所的人数不包括在内。在电子病历(Meditech)中，使用人口统计数据将记录与可用的STBBI结果联系起来。完成了检测率、STBBI阳性率和STBBI检测预测因子的单变量分析。结果:在确定的1824例入院中，1716例可与实验室结果联系。拘留中心的入院人数(n = 105)被排除在外。有72人(4.5%)获得了STBBI测试结果。所有STBBI患者均未接受完整检测。设施检测率在1.9%至11.2%之间，37.5%的STBBI检测结果呈阳性。21例丙型肝炎病毒(HCV)抗体阳性的16例(76.2%)接受了HCV RNA检测，11/16(88.8%)为HCV RNA阳性。机构(p = 0.001)和性别(p = 0.004)是STBBI检测的显著预测因子，而年龄不显著(p = 0.496)。结论:在NL的省级惩教机构中，STBBI检测率很低，而STBBI的患病率，特别是HCV，在被检测者中很高。提高检测率的战略可有助于矫正设施中的STBBI控制。

{"title":"Retrospective review of rates of sexually transmitted and blood-borne infection (STBBI) testing in provincial corrections facilities in Newfoundland and Labrador","authors":"Cindy Whitten, Alison Turner, Brittany Howell, Brooklyn Sparkes, Rosemary Ricciardelli, Peter Daley","doi":"10.3138/jammi-2022-0036","DOIUrl":"https://doi.org/10.3138/jammi-2022-0036","url":null,"abstract":"Background: Sexually transmitted and blood borne infection (STBBI) testing is recommended for people who are incarcerated (PWAI). We sought to determine the rate of STBBI testing during admissions to provincial correctional institutions in Newfoundland and Labrador (NL). Methods: This retrospective cohort study collected the identification of all admissions records in provincial correctional facilities in NL between July 1, 2020 and June 31, 2021 using the Provincial Corrections Offender Maintenance System database. Admissions to provincial detention centers were excluded. Records were linked with STBBI results, when available, within the electronic medical record (Meditech) using demographics. Testing rates, STBBI positivity rates, and univariate analysis of predictors for STBBI testing were completed. Results: Of the 1,824 admissions identified, 1,716 were available for linkage to laboratory results. Admissions to detention centers ( n = 105) were excluded. Any STBBI test result was available for 72 (4.5%) of admissions. No admission had complete testing for all STBBI. Facility testing rates ranged from 1.9 to 11.2% and 37.5% of STBBI tests had any positive results. Sixteen out of the 21 (76.2%) hepatitis C virus (HCV) antibody positives received HCV RNA testing, and 11/16 (88.8%) were HCV RNA positive. Institution ( p = 0.001) and sex ( p = 0.004) were found to be significant predictors of STBBI testing, while age was not significant ( p = 0.496). Conclusions: STBBI testing rates were low in provincial correctional facilities in NL, and STBBI prevalence, especially for HCV, was high among those tested. Strategies to increase the rate of testing could contribute to STBBI control in corrections facilities.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135208133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population-based study of Morganella-Proteus-Providencia group bloodstream infections 摩根菌-变形菌-普罗维登菌群血流感染的人群研究

Q3 Medicine

JAMMI

Pub Date : 2023-09-18 DOI: 10.3138/jammi-2022-0038

Kevin B Laupland, Kelsey Pasquill, Lisa Steele, Elizabeth C Parfitt

Background: There is a paucity of studies investigating the population-based epidemiology of Morganella-Proteus-Providencia (MPP) group infections. Our objective was to determine the incidence, risk factors, and outcome of MPP group bloodstream infections (BSI), and explore species-specific differences. Methods: Population-based surveillance was conducted in the western interior of British Columbia, Canada, between April 1, 2010 and March 30, 2020. Results: Sixty-two incident MPP group BSI occurred for an annual incidence of 3.4 per 100,000 residents; rates for Morganella morganii, Proteus mirabilis, and Providencia species were 0.5, 2.6, and 0.3 per 100,000 population, respectively. The median year of age was 72.5 and was different ( p = 0.03) among the groups. Most (92%) MPP group BSIs were of community-onset. Significant differences were observed in the distribution of clinical focus of infection, with most notably 81% of P. mirabilis BSI due to genitourinary focus as compared to 60% and 22% for Providencia species and M. morganii, respectively. Comorbid illnesses that increased the risk for development of MPP group BSI (incidence rate ratio; 95% CI) were HIV infection (37.0; 4.4–139.6), dementia (11.5; 6.1–20.7), cancer (6.4; 3.2–11.9), stroke 6.5 (2.8–13.3), and diabetes 2.7 (1.3–5.0). Thirteen, one, and none of the cases with P. mirabilis, M. morganii, and Providencia species BSI died within 30 days of index culture for respective all cause case-fatalities of 27%, 11%, and 0% ( p = 0.1). Conclusions: Although collectively responsible for a substantial burden of illness, the epidemiology of MPP group BSI varies significantly by species.

背景:基于人群的Morganella-Proteus-Providencia (MPP)群感染流行病学调查研究较少。我们的目的是确定MPP组血流感染(BSI)的发生率、危险因素和结果，并探讨物种特异性差异。方法:2010年4月1日至2020年3月30日在加拿大不列颠哥伦比亚省西部内陆地区开展人群监测。结果:MPP组发生62例BSI，年发病率为3.4 / 10万;摩根氏摩根氏菌、奇异变形杆菌和普罗维登氏菌的感染率分别为0.5、2.6和0.3 / 10万。中位年龄为72.5岁，组间差异有统计学意义(p = 0.03)。大多数(92%)MPP组脑损伤为社区发病。在临床感染灶分布上观察到显著差异，最明显的是81%的P. mirabilis BSI是由泌尿生殖系统引起的，而普罗维登西亚种和莫氏分枝杆菌分别为60%和22%。增加MPP组BSI发生风险的合并症(发病率比;95% CI)为HIV感染(37.0;4.4-139.6)，痴呆(11.5;6.1-20.7)，癌症6.4;3.2 - -11.9),行程6.5(2.8 - -13.3),2.7(1.3 - -5.0)和糖尿病。在指数培养后的30天内，13例、1例和1例神奇假单胞菌、摩根氏分枝杆菌和普罗维登氏菌BSI病例死亡，全因死亡率分别为27%、11%和0% (p = 0.1)。结论:尽管MPP组BSI共同造成了大量的疾病负担，但其流行病学因物种而异。

{"title":"Population-based study of Morganella-Proteus-Providencia group bloodstream infections","authors":"Kevin B Laupland, Kelsey Pasquill, Lisa Steele, Elizabeth C Parfitt","doi":"10.3138/jammi-2022-0038","DOIUrl":"https://doi.org/10.3138/jammi-2022-0038","url":null,"abstract":"Background: There is a paucity of studies investigating the population-based epidemiology of Morganella-Proteus-Providencia (MPP) group infections. Our objective was to determine the incidence, risk factors, and outcome of MPP group bloodstream infections (BSI), and explore species-specific differences. Methods: Population-based surveillance was conducted in the western interior of British Columbia, Canada, between April 1, 2010 and March 30, 2020. Results: Sixty-two incident MPP group BSI occurred for an annual incidence of 3.4 per 100,000 residents; rates for Morganella morganii, Proteus mirabilis, and Providencia species were 0.5, 2.6, and 0.3 per 100,000 population, respectively. The median year of age was 72.5 and was different ( p = 0.03) among the groups. Most (92%) MPP group BSIs were of community-onset. Significant differences were observed in the distribution of clinical focus of infection, with most notably 81% of P. mirabilis BSI due to genitourinary focus as compared to 60% and 22% for Providencia species and M. morganii, respectively. Comorbid illnesses that increased the risk for development of MPP group BSI (incidence rate ratio; 95% CI) were HIV infection (37.0; 4.4–139.6), dementia (11.5; 6.1–20.7), cancer (6.4; 3.2–11.9), stroke 6.5 (2.8–13.3), and diabetes 2.7 (1.3–5.0). Thirteen, one, and none of the cases with P. mirabilis, M. morganii, and Providencia species BSI died within 30 days of index culture for respective all cause case-fatalities of 27%, 11%, and 0% ( p = 0.1). Conclusions: Although collectively responsible for a substantial burden of illness, the epidemiology of MPP group BSI varies significantly by species.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135208134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Co-infection of SARS-CoV-2 with human coronavirus OC43 in a patient with underlying lung disease: A case report 肺部疾病患者合并感染SARS-CoV-2与人冠状病毒OC43 1例

Q3 Medicine

JAMMI

Pub Date : 2023-09-18 DOI: 10.3138/jammi-2022-0030

Kwadwo Mponponsuo, Yamini Murthy, Jamil Kanji, Alain Tremblay, Daniyal Khan, John Conly, Ranjani Somayaji

Co-infections with SARS-CoV-2 remain relatively rare and there is limited published data on the consequences of these events. We present the case of a 26-year-old man with SARS-CoV-2 and human coronavirus OC43 who had a severe infection resulting in prolonged hospitalization. Consideration of co-infections should be considered in high-risk patients.

与SARS-CoV-2合并感染仍然相对罕见，关于这些事件后果的公开数据有限。我们报告了一名患有SARS-CoV-2和人类冠状病毒OC43的26岁男子的病例，他患有严重感染，导致长期住院。高危患者应考虑合并感染。

引用次数: 0

Are blood cultures the infectious diseases faecal immunochemical test? 血培养是传染病粪便免疫化学试验吗?

Q3 Medicine

JAMMI

Pub Date : 2023-09-18 DOI: 10.3138/jammi-2023-01-31

Kevin B Laupland, Yoav Keynan

Keywords: blood cultures, faecal immunochemical test, infectious diseases, neoplastic diseases, Streptococcus bovisMots-clés : hémocultures, test immunochimique fécal, maladies infectieuses, maladies néoplasiques, Streptococcus bovis

关键词:血液培养，粪便免疫化学检测，传染病，肿瘤疾病，牛链球菌关键词:血液培养，粪便免疫化学检测，传染病，肿瘤疾病，牛链球菌

引用次数: 0

Establishing obstetrics-specific metrics and interventions for antimicrobial stewardship 为抗菌药物管理建立产科特定指标和干预措施

Q3 Medicine

JAMMI

Pub Date : 2023-09-18 DOI: 10.3138/jammi-2022-0032

Jeffrey Man Hay Wong, Denise J Wooding, Sarah E Leung, Vanessa Paquette, Ashley Roberts, Chelsea Elwood

Background: To describe baseline antimicrobial stewardship (AMS) metrics and apply AMS interventions in an inpatient obstetrical population. Methods: From October 2018 to October 2019, our tertiary-care obstetrical center reviewed components of our AMS program, which included: (1) antimicrobial consumption data, (2) point prevalence surveys (PPS), and (3) prospective audit and feedback. We reviewed institutional data for antimicrobial consumption from the pharmacy database. Detailed point prevalence surveys were conducted for all antimicrobial prescriptions on two predefined dates each month. Daily audits and feedback assessed the appropriateness of all non-protocolized antimicrobials. Results: Our average antimicrobial length of therapy (LOT) was 12 days per 100 patient-days, where erythromycin (2.33), amoxicillin (2.28), and ampicillin (1.81) were the greatest contributors. Point prevalence surveys revealed that 28.8% of obstetrical inpatients were on antimicrobials, of which 11.2% were inappropriate. Protocolized antimicrobials were 62% less likely ( p = 0.027) to be inappropriate. From 565 audited prescriptions, 110 (19.5%) resulted in feedback, where 90% of recommendations were accepted and implemented. The most common reasons for interventions include incorrect dosage, recommending a diagnostic test before continuing antimicrobials, and changing antimicrobials based on specific culture and sensitivity. Conclusions: Antimicrobial use in obstetrics is unique compared to general inpatients. We provide a baseline set of metrics for AMS at our obstetrical center intending to lay the groundwork for AMS programming in our discipline. Antimicrobial protocolization, as well as audit and feedback, are feasible interventions to improve antimicrobial prescribing patterns.

背景:描述基线抗菌药物管理(AMS)指标和应用AMS干预在住院产科人群。方法:2018年10月至2019年10月，我们的三级保健产科中心回顾了我们的AMS项目的组成部分，包括:(1)抗菌药物消费数据，(2)点患病率调查(PPS)，(3)前瞻性审计和反馈。我们回顾了药房数据库中抗菌药物使用的机构数据。在每个月预定义的两个日期对所有抗菌药物处方进行详细的点患病率调查。每日审计和反馈评估了所有非规程抗菌药物的适宜性。结果:我们的平均抗菌药物治疗时间(LOT)为12天/ 100患者日，其中红霉素(2.33)、阿莫西林(2.28)和氨苄西林(1.81)贡献最大。点状流行病学调查显示，28.8%的产科住院患者使用了抗菌药物，其中11.2%的患者使用不当。方案规定的抗菌素不适当的可能性降低62% (p = 0.027)。在565张审核处方中，110张(19.5%)产生了反馈，其中90%的建议被接受和实施。干预措施最常见的原因包括剂量不正确，在继续使用抗菌素之前建议进行诊断测试，以及根据特定培养和敏感性改变抗菌素。结论:与普通住院患者相比，产科的抗菌药物使用具有独特性。我们在我们的产科中心为AMS提供了一套基线指标，旨在为我们学科的AMS编程奠定基础。抗菌药物协议以及审计和反馈是改善抗菌药物处方模式的可行干预措施。

{"title":"Establishing obstetrics-specific metrics and interventions for antimicrobial stewardship","authors":"Jeffrey Man Hay Wong, Denise J Wooding, Sarah E Leung, Vanessa Paquette, Ashley Roberts, Chelsea Elwood","doi":"10.3138/jammi-2022-0032","DOIUrl":"https://doi.org/10.3138/jammi-2022-0032","url":null,"abstract":"Background: To describe baseline antimicrobial stewardship (AMS) metrics and apply AMS interventions in an inpatient obstetrical population. Methods: From October 2018 to October 2019, our tertiary-care obstetrical center reviewed components of our AMS program, which included: (1) antimicrobial consumption data, (2) point prevalence surveys (PPS), and (3) prospective audit and feedback. We reviewed institutional data for antimicrobial consumption from the pharmacy database. Detailed point prevalence surveys were conducted for all antimicrobial prescriptions on two predefined dates each month. Daily audits and feedback assessed the appropriateness of all non-protocolized antimicrobials. Results: Our average antimicrobial length of therapy (LOT) was 12 days per 100 patient-days, where erythromycin (2.33), amoxicillin (2.28), and ampicillin (1.81) were the greatest contributors. Point prevalence surveys revealed that 28.8% of obstetrical inpatients were on antimicrobials, of which 11.2% were inappropriate. Protocolized antimicrobials were 62% less likely ( p = 0.027) to be inappropriate. From 565 audited prescriptions, 110 (19.5%) resulted in feedback, where 90% of recommendations were accepted and implemented. The most common reasons for interventions include incorrect dosage, recommending a diagnostic test before continuing antimicrobials, and changing antimicrobials based on specific culture and sensitivity. Conclusions: Antimicrobial use in obstetrics is unique compared to general inpatients. We provide a baseline set of metrics for AMS at our obstetrical center intending to lay the groundwork for AMS programming in our discipline. Antimicrobial protocolization, as well as audit and feedback, are feasible interventions to improve antimicrobial prescribing patterns.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135203182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and predictors of persistent post-COVID-19 symptoms. covid -19后持续症状的患病率和预测因素

Q3 Medicine

JAMMI

Pub Date : 2022-09-27 eCollection Date: 2022-09-01 DOI: 10.3138/jammi-2022-0013

Jose Estrada-Codecido, Adrienne K Chan, Nisha Andany, Philip W Lam, Melody Nguyen, Ruxandra Pinto, Andrew Simor, Nick Daneman

Background: The pandemic has affected hundreds of millions of people; early reports suggesting high rates of prolonged symptoms may be prone to selection bias.

Methods: In a program caring for all SARS-CoV-2 positive inpatients and outpatients between March to October 2020, and offering universal 90-day follow-up, we compared those who died prior to 90 days, not responding to follow-up, declining, or accepting follow-up. Among those seen or declining follow-up, we determined the prevalence and predictors of persistent symptoms.

Results: Among 993 patients, 21 (2.1%) died prior to 90 days, 506 (50.9%) did not respond, 260 (26.1%) declined follow-up because they were well, and 206 (20.7%) were fully assessed. Of 466 who responded to follow-up inquiry, 133 (28.5%) reported ≥1 persistent symptom, including constitutional (15.5%), psychiatric (14.2%), rheumatologic (13.1%), neurologic (13.1%), cardiorespiratory (12.0%), and gastrointestinal (1.7%). Predictors differed for each symptom type. Any persistent symptom was more common in older patients (adjusted odds ratio [aOR] 1.11, 95% CI 1.04 to 1.18/5 years), those diagnosed in hospital (aOR 2.03, 95% CI 1.24 to 3.33) and those with initial constitutional and rheumatologic symptoms. Patients not responding to follow-up were younger and healthier at baseline.

Conclusion: Persistent symptoms are common and diverse 3 months post-COVID-19 but are likely over-estimated by most reports.

背景:这一流行病影响了数亿人;早期报告显示，长期症状的高发率可能倾向于选择偏差。方法:在2020年3月至10月期间照顾所有SARS-CoV-2阳性住院和门诊患者的计划中，并提供普遍的90天随访，我们比较了90天前死亡，对随访无反应，拒绝或接受随访的患者。在那些已见或未见随访的患者中，我们确定了持续症状的患病率和预测因素。结果:993例患者中，90天前死亡21例(2.1%)，无应答506例(50.9%)，健康260例(26.1%)拒绝随访，完全评估206例(20.7%)。在466名接受随访调查的患者中，133名(28.5%)报告了≥1种持续症状，包括体质(15.5%)、精神(14.2%)、风湿病(13.1%)、神经系统(13.1%)、心肺(12.0%)和胃肠道(1.7%)。每种症状类型的预测因子不同。任何持续性症状在老年患者(调整后比值比[aOR] 1.11, 95% CI 1.04至1.18/5年)、在医院确诊的患者(aOR 2.03, 95% CI 1.24至3.33)和有初始体质和风湿病症状的患者中更为常见。对随访无反应的患者在基线时更年轻、更健康。结论:持续症状在covid -19后3个月是常见和多样的，但大多数报告可能高估了症状。

{"title":"Prevalence and predictors of persistent post-COVID-19 symptoms.","authors":"Jose Estrada-Codecido, Adrienne K Chan, Nisha Andany, Philip W Lam, Melody Nguyen, Ruxandra Pinto, Andrew Simor, Nick Daneman","doi":"10.3138/jammi-2022-0013","DOIUrl":"https://doi.org/10.3138/jammi-2022-0013","url":null,"abstract":"Background: The pandemic has affected hundreds of millions of people; early reports suggesting high rates of prolonged symptoms may be prone to selection bias.Methods: In a program caring for all SARS-CoV-2 positive inpatients and outpatients between March to October 2020, and offering universal 90-day follow-up, we compared those who died prior to 90 days, not responding to follow-up, declining, or accepting follow-up. Among those seen or declining follow-up, we determined the prevalence and predictors of persistent symptoms.Results: Among 993 patients, 21 (2.1%) died prior to 90 days, 506 (50.9%) did not respond, 260 (26.1%) declined follow-up because they were well, and 206 (20.7%) were fully assessed. Of 466 who responded to follow-up inquiry, 133 (28.5%) reported ≥1 persistent symptom, including constitutional (15.5%), psychiatric (14.2%), rheumatologic (13.1%), neurologic (13.1%), cardiorespiratory (12.0%), and gastrointestinal (1.7%). Predictors differed for each symptom type. Any persistent symptom was more common in older patients (adjusted odds ratio [aOR] 1.11, 95% CI 1.04 to 1.18/5 years), those diagnosed in hospital (aOR 2.03, 95% CI 1.24 to 3.33) and those with initial constitutional and rheumatologic symptoms. Patients not responding to follow-up were younger and healthier at baseline.Conclusion: Persistent symptoms are common and diverse 3 months post-COVID-19 but are likely over-estimated by most reports.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":"7 3","pages":"208-219"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629726/pdf/jammi-2022-0013.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40682885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Robinsoniella peoriensis: An emerging pathogen and rare cause of wound infection in children. 红伞菌:一种新兴的病原体和儿童伤口感染的罕见原因。

Q3 Medicine

JAMMI

Pub Date : 2022-09-27 eCollection Date: 2022-09-01 DOI: 10.3138/jammi-2021-0038

Carsten Krueger, Marisa Ann Azad, Karamchand Ramotar, Vincent Deslandes, Peter Jessamine

Background: Robinsoniella peoriensis is an anaerobic gram-positive bacilli first isolated from swine manure in 2003 but has since been associated with human infections.

Methods: We describe a pediatric case of R. peoriensis infection following a below-knee amputation for a limb injury and its treatment. Methods of identifying R. peoriensis and reported in vitro antimicrobial minimum inhibitory concentrations from the literature are reviewed.

Results: R. peoriensis is readily identifiable via 16S rRNA gene sequencing and Matrix-Assisted Laser Desorption Ionization-Time of Flight. There is variability in the antibiotic susceptibility profiles reported in the literature, but antibiotics with low in vitro minimum inhibitor concentrations against R. peoriensis include beta-lactam/beta-lactamase inhibitors, carbapenems, vancomycin, and metronidazole.

Conclusion: This is the first reported case of R. peoriensis infection following a traumatic injury in Canada to our knowledge and highlights the importance of recognizing this organism and other anaerobes in settings where wounds are grossly contaminated with soil.

背景:peoriensis Robinsoniella是一种厌氧革兰氏阳性杆菌，2003年首次从猪粪中分离出来，但此后与人类感染有关。方法:我们描述了一个儿童病例的peoriensis感染后，膝下截肢肢体损伤及其治疗。综述了peoriensis的鉴定方法和文献报道的体外最低抑菌浓度。结果:通过16S rRNA基因测序和基质辅助激光解吸电离飞行时间，可以很容易地鉴定peoriensis。文献中报道的抗生素敏感性谱存在差异，但对peoriensis具有低体外最低抑制剂浓度的抗生素包括β -内酰胺/ β -内酰胺酶抑制剂、碳青霉烯类、万古霉素和甲硝唑。结论:据我们所知，这是加拿大首次报道的创伤性损伤后peoriensis感染病例，并强调了在伤口被土壤严重污染的环境中识别这种微生物和其他厌氧菌的重要性。

{"title":"Robinsoniella peoriensis: An emerging pathogen and rare cause of wound infection in children.","authors":"Carsten Krueger, Marisa Ann Azad, Karamchand Ramotar, Vincent Deslandes, Peter Jessamine","doi":"10.3138/jammi-2021-0038","DOIUrl":"https://doi.org/10.3138/jammi-2021-0038","url":null,"abstract":"Background: Robinsoniella peoriensis is an anaerobic gram-positive bacilli first isolated from swine manure in 2003 but has since been associated with human infections.Methods: We describe a pediatric case of R. peoriensis infection following a below-knee amputation for a limb injury and its treatment. Methods of identifying R. peoriensis and reported in vitro antimicrobial minimum inhibitory concentrations from the literature are reviewed.Results: R. peoriensis is readily identifiable via 16S rRNA gene sequencing and Matrix-Assisted Laser Desorption Ionization-Time of Flight. There is variability in the antibiotic susceptibility profiles reported in the literature, but antibiotics with low in vitro minimum inhibitor concentrations against R. peoriensis include beta-lactam/beta-lactamase inhibitors, carbapenems, vancomycin, and metronidazole.Conclusion: This is the first reported case of R. peoriensis infection following a traumatic injury in Canada to our knowledge and highlights the importance of recognizing this organism and other anaerobes in settings where wounds are grossly contaminated with soil.","PeriodicalId":36782,"journal":{"name":"JAMMI","volume":"7 3","pages":"279-282"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629738/pdf/jammi-2021-0038.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40456281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022. 加拿大AMMI实践要点:2021-2022年成人COVID-19治疗。

Q3 Medicine

JAMMI

Pub Date : 2022-09-27 eCollection Date: 2022-09-01 DOI: 10.3138/jammi-2022-08-08

Jennifer M Grant, Justin Chan, Sylvain A Lother, Lisa Barrett, Paul E Bonnar, Aidan R Findlater, Sameer S Kassim, John C Lam, Donald C Vinh

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

JAMMI

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀